This clinical trial is focused on studying a condition known as diminished ovarian reserve, which is a cause of infertility in women. The study will explore the effects of a treatment called low dose hCG priming in women undergoing IVF/ICSI (in vitro fertilization/intracytoplasmic sperm injection). The medication used in this study is called Ovitrelle, which contains the active substance choriogonadotropin alfa. This trial will compare the effects of this medication with a placebo to see if it can help increase the number of eggs retrieved during the IVF/ICSI process.

The purpose of the study is to examine whether using low dose hCG priming for eight weeks can improve outcomes for women with diminished ovarian reserve who are undergoing IVF/ICSI. The study will last for a period of time during which participants will receive either the medication or a placebo. The main focus will be on the number of eggs retrieved, but other factors such as the number of fertilized eggs, embryo quality, and pregnancy rates will also be observed.

Participants will receive the treatment through a subcutaneous injection, which means the medication is injected under the skin. The study aims to confirm findings from a previous pilot study that suggested a significant increase in the number of eggs retrieved could be achieved with this treatment. The trial will help determine if this approach can be beneficial for women facing challenges with fertility due to diminished ovarian reserve.